Sarepta Therapeutics Inc (NAS:SRPT)
$ 121.5 -1.87 (-1.52%) Market Cap: 11.61 Bil Enterprise Value: 11.98 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 86/100

Sarepta Therapeutics Inc To Provide Program Update Transcript

Jan 29, 2024 / 01:30PM GMT
Release Date Price: $120.5 (+1.49%)
Operator

Good morning, ladies and gentlemen, and welcome to the Sarepta Therapeutics Program Update Conference Call. (Operator Instructions) As a reminder, today's program is being recorded. At this time, I'll turn the call over to Doug Ingram, President and Chief Executive Officer. Please go ahead.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Thank you, Michelle, and thanks, everyone, for joining us this morning. Next slide.

Before we begin, I'll remind you to please look to our public filings for a discussion of the various risks and uncertainties that's associated with making forward-looking statements or predictions about the future.

Next slide. We are very pleased to report the results from MOMENTUM Part B, the study examining the expression and safety of SRP-5051 our next-generation peptide conjugated PMO therapy for the treatment of Duchenne patients amenable to Exon 51 skipping. As you'll see SRP-5051, if successful, could be a significant advancement over the current gold standard oligonucleotide therapy for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot